Renaissance Technologies’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Renaissance Technologies’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,400	Closed	-$132K	–	4267
2023 Q2	$132K	Buy	34,400 +1,900	+6%	+$6.97K	﹤0.01%	3407
2023 Q1	$98K	Sell	32,500 -3,894	-11%	-$13.5K	﹤0.01%	3497
2022 Q4	$75K	Buy	36,394 +4,094	+13%	+$12.5K	﹤0.01%	3701
2022 Q3	$112K	Buy	32,300 +4,700	+17%	+$21.4K	﹤0.01%	3557
2022 Q2	$116K	Buy	27,600 +6,685	+32%	+$15.8K	﹤0.01%	3809
2022 Q1	$64K	Sell	20,915 -29,985	-59%	-$115K	﹤0.01%	3871
2021 Q4	$237K	Buy	+50,900	New	+$350K	﹤0.01%	3446
2021 Q3	–	Sell	-15,900	Closed	-$137K	–	3963
2021 Q2	$137K	Buy	+15,900	New	+$140K	﹤0.01%	3321

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $914M AUM

Renaissance Technologies's DBTX Position: Q3 2023 in Review

Renaissance Technologies sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 34,400 shares — an estimated $132K sold.

Renaissance Technologies first reported a position in DBTX in Q2 2021 and held it in 8 quarters. The position peaked at $237K in Q4 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

Renaissance Technologies reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Renaissance Technologies sold 34,400 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $132K.
Renaissance Technologies first reported a position in Decibel Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Renaissance Technologies's Decibel Therapeutics, Inc. Common Stock position peaked at $237K in Q4 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Renaissance Technologies's 13F filing for Q3 2023, filed 14 Nov 2023.